Back to Search
Start Over
Iron oxide nanoparticles attenuate T helper 17 cell responses in vitro and in vivo.
- Source :
-
International immunopharmacology [Int Immunopharmacol] 2018 May; Vol. 58, pp. 32-39. Date of Electronic Publication: 2018 Mar 14. - Publication Year :
- 2018
-
Abstract
- Iron oxide nanoparticles (IONPs) have been shown to attenuate T helper (Th)1 and Th2 cell-mediated immunity in ovalbumin (OVA)-sensitized mice. The objective of this study is to investigate the effects of IONPs on the immune responses of Th17 cells, a subset of T cells involved in various inflammatory pathologies. For in vivo study, a murine model of delayed-type hypersensitivity (DTH) was employed. BALB/c mice received a single dose of IONPs (0.2-10 mg iron/kg) via the tail vein 1 h prior to ovalbumin (OVA) sensitization. Their footpads were subcutaneously challenged with OVA to induce DTH reactions. The expression of Th17 cell-related molecules in inflamed footpads were examined by immunohistochemistry. For in vitro study, OVA-primed splenocytes were directly exposed to IONPs (1-100 μg iron/mL), and then re-stimulated with OVA in culture. The expression of Th17 cell-related molecules were measured by reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay. IONP administration attenuated the number of interleukin (IL)-6, IL-17, the transcription factor ROR-γ, and chemokine receptor 6 positive cells in OVA-challenged footpads, whereas the number of transforming growth factor-β, IL-23 and chemokine (C-C motif) ligand 20 positive cells was not altered. Direct exposure of OVA-primed splenocytes to IONPs suppressed the production of IL-6 and IL-17, and the mRNA expression of IL-17 and ROR-γt. These data indicate that exposure to IONPs attenuates Th17 cell responses in vivo and in vitro.<br /> (Copyright © 2018. Published by Elsevier B.V.)
- Subjects :
- Allergens immunology
Animals
Cells, Cultured
Cytokines metabolism
Disease Models, Animal
Humans
Male
Mice
Mice, Inbred BALB C
Nanoparticles
Nuclear Receptor Subfamily 1, Group F, Member 3 metabolism
Ovalbumin immunology
T-Lymphocyte Subsets immunology
Th17 Cells immunology
Ferric Compounds therapeutic use
Hypersensitivity, Delayed drug therapy
Immunosuppressive Agents therapeutic use
T-Lymphocyte Subsets drug effects
Th17 Cells drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1878-1705
- Volume :
- 58
- Database :
- MEDLINE
- Journal :
- International immunopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 29549717
- Full Text :
- https://doi.org/10.1016/j.intimp.2018.03.007